Duchenne UK Partners with Catabasis to Support Phase 2 Trial of Edasalonexent in DMD
Duchenne UK is partnering with Catabasis Pharmaceuticals to provide financial support for a Phase 2 clinical trial testing the experimental oral therapy edasalonexent in non-ambulatory boys and men with Duchenne muscular dystrophy (DMD). The charity is granting more than $600,000…